Chemosensitization of Plasmodium falciparum by probenecid in vitro
- PMID: 12821454
- PMCID: PMC161864
- DOI: 10.1128/AAC.47.7.2108-2112.2003
Chemosensitization of Plasmodium falciparum by probenecid in vitro
Abstract
Resistance to drugs can result from changes in drug transport, and this resistance can sometimes be overcome by a second drug that modifies the transport mechanisms of the cell. This strategy has been exploited to partly reverse resistance to chloroquine in Plasmodium falciparum. Studies with human tumor cells have shown that probenecid can reverse resistance to the antifolate methotrexate, but the potential for reversal of antifolate resistance has not been studied in P. falciparum. In the present study we tested the ability of probenecid to reverse antifolate resistance in P. falciparum in vitro. Probenecid, at concentrations that had no effect on parasite viability alone (50 microM), was shown to increase the sensitivity of a highly resistant parasite isolate to the antifolates pyrimethamine, sulfadoxine, chlorcycloguanil, and dapsone by seven-, five-, three-, and threefold, respectively. The equivalent effects against an antifolate-sensitive isolate were activity enhancements of approximately 3-, 6-, 1.2-, and 19-fold, respectively. Probenecid decreased the level of uptake of radiolabeled folic acid, suggesting a transport-based mechanism linked to folate salvage. When probenecid was tested with chloroquine, it chemosensitized the resistant isolate to chloroquine (i.e., enhanced the activity of chloroquine). This enhancement of activity was associated with increased levels of chloroquine accumulation. In conclusion, we have shown that probenecid can chemosensitize malaria parasites to antifolate compounds via a mechanism linked to reduced folate uptake. Notably, this effect is observed in both folate-sensitive and -resistant parasites. In contrast to the activities of antifolate compounds, the effect of probenecid on chloroquine sensitivity was selective for chloroquine-resistant parasites (patent P407595GB [W. P. Thompson & Co., Liverpool, United Kingdom] has been filed to protect this intellectual property).
Figures


Similar articles
-
Therapeutic potential of folate uptake inhibition in Plasmodium falciparum.Trends Parasitol. 2004 Mar;20(3):109-12. doi: 10.1016/j.pt.2003.12.005. Trends Parasitol. 2004. PMID: 16676416 Review.
-
Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy.Mol Microbiol. 1999 Jun;32(6):1254-62. doi: 10.1046/j.1365-2958.1999.01437.x. Mol Microbiol. 1999. PMID: 10383765
-
Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.JAMA. 2007 May 23;297(20):2201-9. doi: 10.1001/jama.297.20.2201. JAMA. 2007. PMID: 17519409 Clinical Trial.
-
The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector.Am J Trop Med Hyg. 1998 Feb;58(2):176-82. doi: 10.4269/ajtmh.1998.58.176. Am J Trop Med Hyg. 1998. PMID: 9502601 Clinical Trial.
-
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?Trends Parasitol. 2001 Dec;17(12):582-8. doi: 10.1016/s1471-4922(01)02085-2. Trends Parasitol. 2001. PMID: 11756042 Review.
Cited by
-
Innexins: Expression, Regulation, and Functions.Front Physiol. 2018 Oct 11;9:1414. doi: 10.3389/fphys.2018.01414. eCollection 2018. Front Physiol. 2018. PMID: 30364195 Free PMC article. Review.
-
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy.Malar J. 2012 Feb 9;11:39. doi: 10.1186/1475-2875-11-39. Malar J. 2012. PMID: 22321288 Free PMC article. Review.
-
The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters.J Biol Chem. 2011 Dec 30;286(52):44659-68. doi: 10.1074/jbc.M111.286054. Epub 2011 Oct 13. J Biol Chem. 2011. PMID: 21998306 Free PMC article.
-
Recent highlights in antimalarial drug resistance and chemotherapy research.Trends Parasitol. 2008 Dec;24(12):537-44. doi: 10.1016/j.pt.2008.09.005. Epub 2008 Oct 18. Trends Parasitol. 2008. PMID: 18938106 Free PMC article. Review.
-
Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure.PLoS One. 2012;7(2):e31623. doi: 10.1371/journal.pone.0031623. Epub 2012 Feb 27. PLoS One. 2012. PMID: 22384044 Free PMC article.
References
-
- Antony, A. C. 1996. Folate receptors. Annu. Rev. Nutr. 16:501-521. - PubMed
-
- Banerjee, D., P. Mayer-Kuckuk, G. Capiaux, T. Budak-Alpdogan, R. Gorlick, and J. R. Bertino. 2002. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta 1587:164-173. - PubMed
-
- Bertino, J. R. 1993. Karnofsky Memorial Lecture. Ode to methotrexate. J. Clin. Oncol. 11:5-14. - PubMed
-
- Borst, P., R. Evers, M. Kool, and J. Wijnholds. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295-1302. - PubMed
-
- Borst, P., R. Evers, M. Kool, and J. Wijnholds. 1999. The multidrug resistance protein family. Biochim. Biophys. Acta 1461:347-357. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources